"The mutational diagnostic rate in this series was 77% which is comparable with reports from other populations. Importantly no founder mutations were identified in this case series. Our results add 7 novel PAX6 pathogenic variants to the aniridia-related mutational spectrum and reveal considerable PAX6 allelic heterogeneity in this population."xsd:string